DataVXACS Applied Materials & InterfacesPaper
journal article·2025-11-26

Inhalable Nano-Astaxanthin for Radiation-Induced Lung Injury via Enhanced Lung Retention and Inflammation Suppression

Dongxiao Zhang, Jian He, Jiarong Cui, Ruoxi Wang, Min Zhou

ACS Applied Materials & Interfaces· Volume 17· Issue 47
Publisher page
Source abstract

Abstract

Radiation-induced lung injury (RILI) is a major complication of clinical radiotherapy, characterized by oxidative stress, inflammation, and progressive fibrosis. Astaxanthin (ASX), a potent natural antioxidant, can effectively scavenge radiation-induced reactive oxygen species; however, its therapeutic potential is limited by its poor solubility and bioavailability. Here, we develop inhalable chitosan-modified ASX-loaded PLGA nanoparticles (ASX@P@CS) to prevent RILI. This nanoformulation markedly improves the solubility of ASX, while the cationic chitosan modification enables mucin binding and tight-junction modulation, thereby enhancing the pulmonary permeability and retention. As a result, ASX@P@CS achieves superior intrapulmonary distribution, significantly attenuates acute oxidative damage and inflammation, and prevents chronic fibrotic remodeling in mouse models of RILI. This work establishes a biocompatible inhalable nano-astaxanthin platform with long-term biosafety, offering a promising strategy for the clinical prevention of radiation-induced lung injury.
Source: openalex_inverted_index · Quality: baseline

Research context

NanomaterialsBiomaterials

OpenAlex topics: Effects of Radiation Exposure · Radiation Therapy and Dosimetry · Chemotherapy-induced cardiotoxicity and mitigation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Eye Center, The Second Affiliated Hospital, School of Medicine, and Liangzhu Laboratory

Zhejiang University

Zhejiang University-University of Edinburgh Institute (ZJU-UoE Institute), Zhejiang University School of Medicine

Department of Radiation Oncology

Zhejiang Cancer Hospital

Hangzhou Institute of Medicine (HIM)

Chinese Academy of Sciences

Zhejiang University-Ordos City Etuoke Banner Joint Research Center

Research Center for Life Science and Human Health, Binjiang Institute of Zhejiang University

State Key Laboratory of Transvascular Implantation Devices

Funding

China Postdoctoral Science Foundation · National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Opening Foundation of the State Key Laboratory of Transvascular Implantation Devices · Key Research and Development Project of Zhejiang Province · Postdoctoral Science Preferential Funding of Zhejiang Province · Binjiang Institute of Zhejiang University

References (42)

Show source-provided references
1. 10.1021/acsami.4c2158910.1021/acsami.4c21589 ↗
2. 10.1021/acsami.3c0050210.1021/acsami.3c00502 ↗
3. 10.1021/acsami.5c0613210.1021/acsami.5c06132 ↗
4. 10.1021/acsami.3c0132210.1021/acsami.3c01322 ↗
5. 10.1186/s13014-020-01654-910.1186/s13014-020-01654-9 ↗
6. 10.1016/j.chest.2019.03.03310.1016/j.chest.2019.03.033 ↗
7. 10.3389/fonc.2019.0087710.3389/fonc.2019.00877 ↗
8. 10.1186/s12890-020-01376-410.1186/s12890-020-01376-4 ↗
9. 10.21037/tlcr-22-10810.21037/tlcr-22-108 ↗
10. 10.1016/j.adro.2019.08.01010.1016/j.adro.2019.08.010 ↗
11. 10.1016/S1470-2045(03)01191-410.1016/S1470-2045(03)01191-4 ↗
12. 10.3389/fcell.2022.110030510.3389/fcell.2022.1100305 ↗
13. 10.1038/s41467-023-42171-z10.1038/s41467-023-42171-z ↗
14. 10.1016/S0167-7799(03)00078-710.1016/S0167-7799(03)00078-7 ↗
15. 10.1016/j.phrs.2021.10547910.1016/j.phrs.2021.105479 ↗
16. 10.1186/1743-7075-7-1810.1186/1743-7075-7-18 ↗
17. 10.3390/md1909051110.3390/md19090511 ↗
18. 10.3390/md1808040610.3390/md18080406 ↗
19. 10.1038/nrd215310.1038/nrd2153 ↗
20. 10.1038/s41586-023-06809-810.1038/s41586-023-06809-8 ↗
21. 10.1038/s41563-023-01475-710.1038/s41563-023-01475-7 ↗
22. 10.1021/acsnano.3c0150210.1021/acsnano.3c01502 ↗
23. 10.1038/s41598-019-47208-210.1038/s41598-019-47208-2 ↗
24. 10.1016/j.semradonc.2006.11.00510.1016/j.semradonc.2006.11.005 ↗
25. 10.1016/j.canlet.2011.12.01210.1016/j.canlet.2011.12.012 ↗
26. 10.1038/s42255-022-00591-z10.1038/s42255-022-00591-z ↗
27. 10.3389/fdsfr.2023.122776310.3389/fdsfr.2023.1227763 ↗
28. 10.1021/acs.molpharmaceut.1c0037010.1021/acs.molpharmaceut.1c00370 ↗
29. 10.1038/nrm.2016.8010.1038/nrm.2016.80 ↗
30. 10.1002/adma.20200755710.1002/adma.202007557 ↗
31. 10.1016/j.ijrobp.2006.08.05810.1016/j.ijrobp.2006.08.058 ↗
32. 10.3390/cancers1206156110.3390/cancers12061561 ↗
33. 10.1016/j.radonc.2011.12.01810.1016/j.radonc.2011.12.018 ↗
34. 10.2144/00011272910.2144/000112729 ↗
35. 10.1016/j.radonc.2010.09.00210.1016/j.radonc.2010.09.002 ↗
36. 10.1002/adhm.20230175810.1002/adhm.202301758 ↗
37. 10.1021/acsami.8b0094910.1021/acsami.8b00949 ↗
38. 10.1021/acsnano.6b0581010.1021/acsnano.6b05810 ↗
39. 10.1016/j.ajpath.2017.06.01310.1016/j.ajpath.2017.06.013 ↗
40. 10.1038/s41467-020-15344-310.1038/s41467-020-15344-3 ↗
41. 10.1136/jcp.41.4.46710.1136/jcp.41.4.467 ↗
42. 10.4081/mrm.2017.23010.4081/mrm.2017.230 ↗